Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
609.00    -7.00 (-1.14%)
Bid:
609.00
Ask:
611.00
Spread: 2.00 (0.328%)
Market Cap: £530.59m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

AGM & Q1 Interim Management Statement

10 Feb 2023 07:00

RNS Number : 5110P
Victrex PLC
10 February 2023
 
 

10 February 2023

Victrex plc - AGM & Q1 Interim Management Statement

'A steady start: pricing ahead of expectations and revenue up 6%, despite volume softness'

Victrex plc is an innovative world leader in high performance polymer solutions, delivering sustainable products which enable environmental and societal benefit in multiple end-markets. Today's Interim Management Statement (IMS) covers the first quarter of FY 2023 from 1 October 2022 to 31 December 2022.

 

Overall, the Group saw a steady start, in what is typically the seasonally weakest quarter. Average selling prices (ASP) were ahead of expectations, with good momentum from price increases and surcharge pricing. This helped to drive revenue up 6%, despite an 8% decline in Q1 volume; slightly softer than anticipated.

Highlights

· Q1 Group revenue £78.8m up 6% (Q1 2022: £74.6m)

· ASP up 14% at £83/kg and slightly ahead of expectations; driven by sales mix, annualised price increases, surcharge pricing and currency

· Q1 Group sales volume of 948 tonnes down 8% on the prior year (Q1 2022: 1,025 tonnes)

· Supporting TechnipFMC for Brazil scale-up ahead of bid outcome for Magma pipe opportunity

· Share buybacks now included alongside special dividends for excess cash return options, following shareholder engagement

 

End market performance

Q1 performance reflected reduced activity across several Industrial end markets, particularly in Europe, together with some normalisation within Value Added Resellers (VAR) after a period of strong growth. The Group saw growth in Aerospace and Automotive during the period, which was offset by weakness in Electronics and Energy & Industrial.

 

In Medical, we continue to see a good performance. Q1 revenue was strongly ahead of the comparative period, which included the impact of Covid-19 variants and lockdowns in the US, in Europe and Asia.

 

Mega-programmes

The Group has an attractive portfolio of short, medium and long-term growth opportunities, including seven 'mega-programmes' offering potentially game changing growth opportunities. 

 

In our Magma mega-programme, which is based on thermoplastic composite pipe for the energy industry using Victrex PEEK, Victrex composite tape and Victrex's pipe extrusion know-how, we continue to support TechnipFMC for qualification and scale-up at a new facility in Brazil. Bid outcomes for a key offshore programme in Brazil are anticipated over the coming months, offering the potential opportunity for significant annual volumes, over a multi-year period.

 

In our PEEK Knee mega-programme, we have seen further strong progress. Patient recruitment to the Maxx Orthopaedics clinical trial is largely complete, with 33 implanted patients. Ten patients have passed the primary end-point for the clinical trial (15 months), with no issues or intervention required. Two patients will pass the two-year implant stage this month. In Trauma, In2Bones has continued to make strong progress, with our PEEK composite based Trauma plates now being implanted in over 80 patients.

 

Financial position

Victrex retains a highly cash generative business model, supporting growth investment alongside attractive shareholder returns. Available cash of £60.8m at 31 December 2022 (excluding £2.3m of cash ringfenced in our Chinese subsidiaries), is prior to payment of the 2022 final dividend on 17 February. 

 

Outlook

Jakob Sigurdsson, Chief Executive of Victrex, said: "Expectations for the full year are unchanged at this early stage. We are encouraged by modest revenue growth, a better sales mix and improved selling prices. We also continue to make good progress in recovering energy and raw material inflation.

 

"However, the Group saw softer volumes during Q1 and the macro-economic environment remains uncertain, with ongoing weakness in several end-markets. In line with Victrex's historic performance, we remain well positioned for when end-markets improve.

 

"With sustainable products and a strong pipeline of growth opportunities, our Polymer & Parts strategy keeps us well positioned for the medium to long-term."

 

Analyst & investor conference call

A conference call with management will take place this morning, Friday 10th February 2023, at 08.30am GMT. Access to the call is via the following link: https://cossprereg.btci.com/prereg/key.process?key=PYTAVPVQF

 

Annual General Meeting

Victrex's Annual General Meeting will also be held today, starting at 11.00am GMT and taking place at JP Morgan, 1 John Carpenter Street, London EC4Y 0JP.

 

Victrex plc:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG +44 (0)7809 595831

Ian Melling, Chief Financial Officer +44 (0)1253 897700

Jakob Sigurdsson, Chief Executive +44 (0)1253 897700

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to energy operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, enable environmental and societal benefit for our customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRFUPUPCPUPWGRB
Date   Source Headline
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding
31st Jul 202412:20 pmRNSTotal Voting Rights
5th Jul 20242:02 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSQ3 Interim Management Statement
28th Jun 20249:52 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.